Biomedical subjects

H Satoh

Publications and source records attributed to H Satoh.

1,054 records · Page 59Linked to original sources

PubMedDate not supplied

Clinical application of percutaneous left ventricular support with a centrifugal pump.

A percutaneous left ventricular support (PLVS) system can play an important role in the short-term support of patients with severe heart failure, but these devices are not available for clinical use. We devised a new transseptal left atrial (LA) cannula for PLVS without thoracotomy. The cannula is 21 Fr in size (internal diameter: 5.3 mm) and 65 cm in length. This transseptal LA cannula can be inserted easily into the left atrium under fluoroscopy, by the usual transseptal technique, using a conventional Brockenbrough's needle. PLVS was used in two patients who developed cardiogenic shock following acute myocardial infarction and underwent resuscitation using percutaneous cardiopulmonary support (PCPS). The patients could not be weaned from PCPS even after successful percutaneous transluminal coronary angioplasty (PTCA), and PLVS provided 3.0 L/min of assist flow. The duration of PLVS was 114 and 92 hr. Both patients were weaned from PLVS, and one survived. There were no complications related to the PLVS. PLVS with a new transseptal LA cannula may be effective and useful for patients with severe heart failure.

Heart Failure↗

PubMedDate not supplied

Advantage of in vivo chemosensitivity assay to detect vincristine-resistance in a human epidermoid carcinoma xenograft.

We examined both in vitro and in vivo chemosensitivity of the human epidermoid carcinoma xenograft xeKB3-1-R which shows overexpression of the multidrug resistance gene (MDR1). XeKB3-1-R was sensitive to vincristine (VCR, 6%) and doxorubicin (DOX, 9%) in the adhesive tumor cell culture system in vitro. However, this xenograft showed decreased sensitivity to VCR (65%) and DOX (42%) in an in vivo chemosensitivity assay. The in vivo resistance of xeKB3-1-R to both VCR and DOX was reversed by coadministration of cyclosporin A (VCR 22%, DOX 11%). The xenograft xeKB3-1-R expressed significantly higher levels of MDR1 than xeKB3-1. The results confirmed that multidrug resistance in xeKB3-1-R was related to enhanced MDR1 expression in vivo. The observed discrepancies between in vitro and in vivo chemosensitivities suggest that the in vivo sensitivity assay more accurately reflects drug resistance as a result of low-level MDR1 overexpression in solid tumors.

Animals↗

PubMedDate not supplied

Outcome of patients with lung cancer detected by mass screening versus presentation with symptoms.

Lung cancers in the early stages are frequently detected via mass screening in Japan. The aim of this study is to evaluate the outcome of patients with lung cancer detected via mass screening and to compare them to those in whom the malignancy was detected by symptoms. A total of 774 untreated patients with lung cancer who were admitted to Department of Respiratory Medicine, Tsukuba University Hospital over a 20 year period up to 1995, were analyzed with reference to their reasons for detection of the cancer. In the mass screened group(116 patients), 50.0% of lung cancer was detected at stage I of TNM classification, while only 8.2% of patients with symptoms(561 patients) had stage I lung cancer (p = 0.0001). As lung cancers detected via mass screening were more often at operable stage (stage I, II or IIIA) (p = 0.0001), surgical treatment was chosen more frequently in the mass screened group(p = 0.0001). The outcome of patients with lung cancer detected via mass screening was more favorable than that of the patients detected by their symptoms (p = 0.0002). The early detection of lung cancer via mass screening contributes to improvement of the outcome.

Adenocarcinoma↗

PubMedDate not supplied

Pleural effusion as a significant prognostic factor in non-small cell lung cancer.

UNLABELLED: In non-small cell lung cancer (NSCLC), pleural effusion is a frequently observed complication, and often provides a treatment difficulties. The aim of this study is to evaluate prognostic significance of pleural effusion in patients with NSCLC. MATERIALS AND METHODS: Seven hundred and eight untreated patients with NSCLC who were consecutively admitted to our department over a 20 year period up to December 1996, were analyzed using uni- and multivariate analyses. RESULTS: Univariate analysis showed pleural effusion to be a significant prognostic factor for NSCLC, in addition to gender, stage, performance status(PS). Multivariate analysis proved pleural effusion to be one of the significant prognostic factors, especially in patients with poor PS. CONCLUSION: Adequate palliative care to provide prolonged quality survival remains the primary goal of therapy for patients with poor performance status and pleural effusion until better treatments are developed.

Adult↗

PubMedDate not supplied

Combined effects of TNP-470 and taxol in human non-small cell lung cancer cell lines.

The effects of TNP-470, one of the promising antiangiogenic agents and taxol when combined were evaluated in two human cultured cell lines derived from non-small cell lung cancer(NSCLC). Cytotoxicity was determined using a tetrazolium salt(MTT) assay. The inhibitory effects of TNP-470 on cell proliferation were dose related and the 50% inhibitory concentration on these cell lines were 50.0 to 62.5 microM. Evaluation of drug interactions with isobologram and the combination index values showed that sequential exposure to taxol followed by TNP-470 produced synergistic effects in these cell lines tested. Our findings suggest that such an angiocytotoxic chemotherapy might be promising for the treatment of NSCLC.

Antineoplastic Combined Chemotherapy Protocols↗

PubMedDate not supplied

Lung cancer cell line producing cytokeratin 19 fragment and sialyl Lewis X-i antigen.

A new human lung large cell carcinoma cell line producing cytokeratin 19 fragment(CYFRA) and sialyl Lewis X-i antigen(SLX), designated TKB-13, was established from a patent in our laboratory. The cell line grew in a monolayer and had a polygonal epitheloid appearance in phase-contrast microscopy. The doubling time of TKB-13 cells was approximately 32 hours in Dulbecco's minimal essential medium with 5% fetal bovine serum. TKB-13 cells could be transplanted to nude mice and the histological characteristics were the same as those of resected tissue from the primary site. Positive reactions for CYFRA and for SLX were seen within the cytoplasm of TKB-13 cells by immunocytochemical staining. Both CYFRA and SLX were detected in the culture supernatant. Our results suggested that TKB-13 cell line is available for experimental studies on the biological behavior of non-small cell lung cancer.

Aged↗

PubMedDate not supplied

Analysis of long-term survivors after platinum containing chemotherapy in advanced non-small cell lung cancer.

Among 195 patients with locally advanced or metastatic non-small cell lung cancer(NSCLC), we evaluated the characteristics of two-year survivors. All the patients with stage IIIA-IV disease received platinum containing combination chemotherapy at Tsukuba University Hospital between 1985 and 1996. Fourteen patients (7.2%) and 7 patients (3.6%) survived for more than 2 and 3 years, respectively. Ten of the 14 responded to initial chemotherapy, and 9 patients received additional treatment such as thoracic irradiation and/or surgical resection. Three of the 14 patients survived more than 5 years disease free, one of them survived more than 10 years. From the results uni- and multivariate analyses of these patients, early stage of the disease, low number of metastatic site, without associated lung disease were confirmed as significant determinants of survival. This study revealed that a small proportion of patients with advanced NSCLC might be potentially curable with appropriate treatment.

Adult↗

PubMedDate not supplied

Predictive value of preoperative serum sialyl Lewis X-i antigen levels in non-small cell lung cancer.

BACKGROUND AND STUDY OBJECTIVE: Serum sialyl Lewis X-i antigen has been shown to be one of the most specific markers for monitoring non-small cell lung cancer(NSCLC). We evaluated the correlation between serum levels of sialyl Lewis X-i antigen and mediastinal lymph node involvement in NSCLC patients. METHODS: One hundred patients with untreated NSCLC were included in this study. All the patients received surgical treatment and the lymph nodes were evaluated pathologically. Pretreatment sera from these patients examined for the levels of sialyl Lewis X-i antigen, using a radioimmunoassay. RESULTS: Serum levels of sialyl Lewis X-i antigen levels in patients with N2 were higher than those of N0-1(p = 0.0049). According to the receiver characteristic curve analysis, the recommended cut-off level of the antigen between N0-1 patients and N2 patients was 38.0 U/ml. CONCLUSION: Measurement of serum levels of sialyl Lewis X-i antigen might provide preoperative information in patients with NSCLC.

Aged↗

PubMedDate not supplied

Patterns of pancreatic metastasis from lung cancer.

BACKGROUND: Metastatic involvement of the pancrease is not an uncommon autopsy finding, however, pancreatic metastasis is an infrequent clinical condition and the pattern of the metastases have not been studied. We conducted a retrospective study in order to evaluate the pattern of the metastasis from lung cancer. PATIENTS: From 1976 to 1997, 26 patients with pancreatic metastasis were identified by searching the medical records of 850 patients with lung cancer. RESULTS: The usual pattern of pancreatic metastasis involved a solitary nodule in 19 patients (73.1%); multiple nodules in 3(11.5%), and diffuse swelling in 4(15.4%). Nineteen(73.1%) and 18(69.2%) of 26 patients had liver and adrenal gland metastases, respectively. CONCLUSIONS: Pancreatic metastasis represents a common site of extrathoracic spread of disease for the small number of patients with advanced lung cancer, especially in small cell lung cancer. The usual pattern of the metastasis is a solitary nodule. In order to diagnose exactly, abdominal CT scan would be helpful in such metastasis.

Adult↗

PubMedDate not supplied

Use of daily low-dose carboplatin in radiotherapy for non-small cell lung cancer.

The feasibility of using low-dose carboplatin (CBDCA) as a radiopotentiator in radiotherapy(RT) for non-small cell lung cancer(NSCLC) patients with unfavorable factors was studied. Fifteen patients with locally advanced and inoperable NSCLC were treated with RT in combination with daily 20 mg/m2 CBDCA. Twelve patients completed the treatment as planned. Thrombocytopenia and leukocytopenia(WHO Grade > or = 3) were observed in 1 and 2 patients, respectively. A complete and a partial response were obtained in 1(6.7%) and 9(60%) patients, respectively. The median survival time was 11 months. Calvert's formula has been used for carboplatin dosing and creatinine clearance applies in place of glomerular filtration rate in the formula. In this schedule, there was no correlation between pretreatment creatinine clearance and the nadir of platelet count(p = 0.9016). The combined use of daily low-dose CBDCA to RT was feasible for NSCLC patients with unfavorable factors.

Adenocarcinoma↗